AI and Machine Learning – Changing the Health Care Landscape

But Don’t Exclude Sterile Processing from Key Discussions By David Taylor, MSN, RN, CNOR Ancient papyrus revealed Egyptian medical practice was highly advanced and doctors performed the first surgery more than 3,500 years ago (2750 BC).[1, 2] Since then, medicine has...

The Concept of Modular Credentials

By James X. Stobinski, PhD, RN, CNOR, CSSM (E) Recently, during the question and answer period following a presentation, I was asked how the Competency and Credentialing Institute (CCI) is evolving in response to the COVID-19 pandemic. The context for this question...

Reopening to the New Normal

By Bill Prentice From early March through the end of April, it seemed that almost everyone I talked to used the word “coronavirus” or “COVID-19” at some point in our conversation. ASCA staff worked seven days a week during that time, conferring with federal and state...

Why Air Disinfection Systems are Becoming an Increasingly Vital Component of Patient Care

Sponsored by Avante Health Solutions By Brent Kramer Medical facilities are incorporating air filtration systems to help safeguard patients and staff from coronavirus transmission. As coronavirus restrictions ease across the United States, medical facilities are...

New FDA Actions to Promote the Safe Use of Surgical Staplers and Staples for Internal Use: Proposed Reclassification, Draft Guidance, and Public Panel Meeting

The U.S. Food and Drug Administration (FDA) is concerned by the large number of adverse events associated with surgical staplers and staples specifically for internal use. We are taking multiple actions to help promote patient safety and reduce the risk of adverse events associated with these devices.

Between January 1, 2011 and March 31, 2018, the FDA received over 41,000 medical device reports related to surgical staplers and staples for internal use, including 366 reported deaths, over 9,000 serious injuries, and over 32,000 malfunctions.

As first announced in our March 8, 2019, letter to healthcare providers, the FDA has now issued:

  • A draft guidance, “Surgical Staplers and Staples for Internal Use – Labeling Recommendations,” to help manufacturers develop labeling with information about specific risks, limitations, and directions for use of the device, which is open for public comment through June 24, 2019.
  • A proposed order to reclassify surgical staplers for internal use from Class I to Class II medical devices, which is open for public comment through June 24, 2019.
  • Currently, surgical staplers for internal use are regulated as Class I medical devices, which do not require a premarket submission to the FDA.
  • Classification as a Class II device would allow the FDA to establish mandatory special controls and require premarket notification (510(k)).
  • A Federal Register notice formally announcing an open public meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. On May 30, 2019, the committee will discuss and make recommendations regarding the proposed reclassification of surgical stapler devices for internal use from Class I (general controls) to Class II (special controls).

We invite any interested parties to participate in the public panel meeting, either by attending the meeting, presenting at the meeting, or submitting written comments.



Submit a Comment

Your email address will not be published. Required fields are marked *